Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
10:42:22 EDT Sun 22 Jun 2025
Enter Symbol
or Name
USA
CA



Q:SPRY - ARS PHARMACEUTICALS INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
SPRY - Q0.615.00·16.250.215.80-0.11-0.71,338.120,54110,83815.99  16.11  15.4518.51  7.5517:43:17May 2715 min RT 2¢

Recent Trades - Last 10 of 10838
Time ETExPriceChangeVolume
17:43:17Q15.8399-0.0701500
16:20:00Q15.80-0.11958
16:14:55Q15.80-0.118,198
16:11:38Q15.80-0.111,918
16:08:16Q15.47-0.4420
16:04:20Q15.80-0.11124
16:04:15Q15.80-0.111
16:04:15Q15.80-0.111
16:04:06Q15.80-0.11521
16:04:02Q15.80-0.1166

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-05-27 08:01U:SPRYNews ReleaseARS Pharmaceuticals to Participate in Upcoming Investor Conferences
2025-05-14 07:00U:SPRYNews ReleaseARS Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Progress in U.S. Commercial Launch of neffy(TM) (epinephrine nasal spray)
2025-05-07 08:00U:SPRYNews ReleaseARS Pharmaceuticals' neffy(TM) (epinephrine nasal spray) 1 mg is Now Available in the United States for Type I Allergic Reactions, including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms
2025-05-05 08:00U:SPRYNews ReleaseARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2025 Financial Results
2025-05-02 08:00U:SPRYNews ReleaseARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and Global Allergy Leader ALK-Abello A/S to Expand Reach of neffy(TM) (epinephrine nasal spray) to Additional U.S. Pediatricians
2025-03-20 07:00U:SPRYNews ReleaseARS Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
2025-03-05 16:10U:SPRYNews ReleaseARS Pharmaceuticals Announces FDA Approval of neffy(TM) 1 mg (epinephrine nasal spray) for Type I Allergic Reactions, Including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms
2025-03-03 16:35U:SPRYNews ReleaseARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2024 Financial Results and Participation at Upcoming Conferences
2025-02-20 19:02U:SPRYNews ReleaseARS Pharmaceuticals Announces OptumRx, Cigna Healthcare and Navitus Health Systems Add neffy(TM) (Epinephrine Nasal Spray) to National Formularies, Further Expanding Coverage for Patients
2025-02-18 08:00U:SPRYNews ReleaseARS Pharmaceuticals to Showcase Innovation and Present Data on neffy(TM) (epinephrine nasal spray) at 2025 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting
2025-02-05 08:00U:SPRYNews ReleaseARS Pharmaceuticals to Participate in the Oppenheimer 35th Annual Healthcare Conference
2025-01-21 08:00U:SPRYNews ReleaseARS Pharmaceuticals Launches neffyinSchools Program Providing Free Life-Saving Needle-Free Epinephrine For Emergency Use to Eligible K-12 Schools
2025-01-13 08:00U:SPRYNews ReleaseARS Pharmaceuticals Announces Preliminary Fourth Quarter 2024 Financial Results and 2025 Objectives for neffy(TM) (epinephrine nasal spray)
2025-01-06 08:00U:SPRYNews ReleaseARS Pharmaceuticals Files for Approval of neffy(TM) in Canada and the United Kingdom on Behalf of Licensing Partner ALK-Abello A/S
2024-12-19 17:25U:SPRYNews ReleaseARS Pharmaceuticals Announces neffy(TM) (Epinephrine Nasal Spray) is available on Express Scripts Commercial National Formularies
2024-12-18 08:00U:SPRYNews ReleaseARS Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
2024-12-12 14:33U:SPRYNews ReleaseARS Pharmaceuticals Announces Filings for Approval of neffy(TM) in China, Japan and Australia
2024-12-04 08:00U:SPRYNews ReleaseARS Pharmaceuticals Announces Planned Launch of neffyinSchools Program to Provide Life-Saving Needle Free Epinephrine to Eligible K-12 Schools at No Cost
2024-11-13 06:30U:SPRYNews ReleaseARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates
2024-11-11 07:00U:SPRYNews ReleaseARS Pharmaceuticals Announces Exclusive Agreement with Global Allergy Leader ALK to Commercialize neffy(TM) in Europe, Canada and Other Geographies Outside the United States